AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Penumbra shows stronger financial performance with higher revenue and earnings compared to Beyond Air.
- Beyond Air, with a lower valuation ratio, presents a more affordable investment option per market metrics.
- Institutional ownership favors Penumbra, indicating confidence in its long-term growth potential.
Penumbra, Inc. (NYSE:PEN) specializes in designing, developing, manufacturing, and marketing medical devices worldwide. Its broad product range covers peripheral devices, access products, as well as solutions for neuro and peripheral embolization. Operating out of Alameda, California, since its inception in 2004, Penumbra has made significant strides in the medical device industry.
On the other hand, Beyond Air, Inc. (NASDAQ:XAIR) operates as a commercial-stage medical device and biopharmaceutical company. It focuses on the development of the LungFit platform, nitrogen oxide generation, and delivery systems. Based in Garden City, New York, Beyond Air targets conditions like pulmonary hypertension in newborns and viral lung infections such as COVID-19.
Valuation & Earnings
A close look at financials reveals Penumbra's robust performance with gross revenue reaching $1.06 billion against Beyond Air’s $1.16 million. While Penumbra's earnings per share (EPS) stand at $0.86, Beyond Air shows a loss per share of $1.41, highlighting Penumbra's firm profitability. However, Beyond Air’s enticing price-to-earnings ratio, markedly lower, suggests a more accessible investment opportunity.
Risk and Volatility
Analyzing the risk metrics, Penumbra maintains a beta of 0.53, indicating lower volatility compared to the market benchmark. Beyond Air, contrastingly, posts a beta of -0.15, pointing towards a share price remarkably less volatile than Penumbra. This aspect invites investors seeking stability to consider the differences in market sensitivity.
Institutional and Insider Ownership
Institutional investors hold substantial stakes in Penumbra, owning 88.9% of its shares, suggesting strong market confidence in its potential growth trajectory. Beyond Air, with 31.5% institutional ownership, holds a lesser share. However, insider ownership tells a different story, with 20.1% for Beyond Air against 5.0% for Penumbra, indicating a significant belief by Beyond Air’s insiders in the company’s future performance.
Profitability
Profitability metrics further emphasize Penumbra's dominance, recording positive net margins of 2.97% and a commendable return on assets and equity. Beyond Air's metrics, unfortunately, show profound negative profitability, illustrating the challenges it faces in achieving financial breakeven.
In a comparative examination of Penumbra and Beyond Air, Penumbra emerges as the stronger entity on numerous fronts, including financial health, institutional trust, and profitability. Beyond Air, however, presents a disruptive alternative with its innovative medical solutions, especially in emerging therapeutic areas.
